PD-L1 PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance

PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Bristol-Myers Squibb Company

The purpose of this study is to evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation which may impact outcomes (survivals and/or pattern of metastasis) of lung adenocarcinoma. This may help determine the progression/overall survival of patients with K-RAS-mutated non-small cell lung cancer.